Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress
These data support clinically meaningful efficacy within this patient population. We observed a high rate of complete responses in patients with laCSCC
POSEIDON is among the largest global datasets to quantify this residual inflammatory burden
Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
India already has talent, digital infrastructure, entrepreneurial energy, clinical expertise, and policy momentum. The next phase demands coordinated execution and building institutions that can hold the ecosystem together over time
Dual regulatory clearances for Sentire(R) Endoscopic surgical system strengthen the company’s expansion across Europe and Asia-Pacific in minimally invasive robotic surgery
The decision clears the drug as a monotherapy for adults with unresectable, locally advanced or metastatic non-small cell lung cancer
The company is expected to conduct further studies to confirm the long-term efficacy and safety of Vijoice in both adult and paediatric patients
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
Clearance marks major shift beyond chemotherapy
Subscribe To Our Newsletter & Stay Updated
